MetaCap

Roivant Sciences Ltd. (ROIV)

NASDAQ: ROIVHealth CareBiotechnology: Pharmaceutical PreparationsUSD

38.66-0.305 (-0.78%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ROIV stock chart

Technical analysis

Key statistics

All statistics
Market cap
$28.01B
EPS (TTM)
-$0.65
52-week range
19.96 – 42.50
Day range
38.46 – 39.51
Volume / Avg
3.97M / 8.13M
Beta
—

52-week range

$19.96$42.50

ROIV stock today

Shares of Roivant Sciences (ROIV) finished lower on Nov 20 at $38.66, a drop of 0.78% or $0.305 per share, versus the S&P 500's 3.70% decline. Trading was light, with 3.97M shares changing hands, about 49% of the average daily volume. At this level, ROIV sits near the top of its 52-week range of $19.96 to $42.50: 9.0% below the high, set on Sep 8, 2026 and 93.7% above the low.

ROIV is up 78.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 91.2%. Roivant Sciences has posted a net loss over the last twelve months (EPS of -$0.65), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Roivant Sciences

Company profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Matthew Gline
Headquarters
London
Employees
721

Financial highlights

Full financials

In fiscal 2025, Roivant Sciences generated $8.3 million in revenue, down 71.6% from fiscal 2024, its first annual decline since 2024. Roivant Sciences reported a net loss of $299.8 million, compared with a loss of $172.0 million a year earlier. Operating margin was -6235.7%.

Roivant Sciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2023FY 2022
Revenue$8.26M$29.05M$32.71M$31.53M$55.29M
Growth-71.57%-11.19%+3.75%-42.97%+132.34%
Net income$-299.77M$-171.98M$4.35B$-1.01B$-845.26M
EPS (diluted)$-0.54$-0.24$5.23$-1.42$-1.26

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$50.82+31.47%

  • Strong buy 2
  • Buy 9
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $42.00High $62.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.27 vs $-0.52
Surprise
+48.08%

ROIV news

All ROIV news

Roivant Sciences peers

Health Care sector
ROIV peer companies
CompanyPrice% ChgMarket capCompare
INSMInsmed Incorporated141.33-2.17%$31.01Bvs ROIV
GMABGenmab A/S ADS50.60-1.46%$31.20Bvs ROIV
ZTSZoetis Inc. Class A79.11-2.08%$32.14Bvs ROIV
UTHRUnited Therapeutics Corporation554.73-0.78%$23.63Bvs ROIV
VTRSViatris Inc.19.63-1.26%$22.50Bvs ROIV
ALNYAlnylam Pharmaceuticals Inc.143.82-2.71%$19.26Bvs ROIV
RPRXRoyalty Pharma plc Class A68.45+1.08%$39.36Bvs ROIV
ASNDAscendis Pharma A/S252.73-1.26%$16.58Bvs ROIV

Indexes, lists and sector

Roivant Sciences stock FAQ

What is Roivant Sciences's stock price today?

ROIV last traded at $38.66 as of Nov 20, 4:00 PM EST, down 0.78% on the day. Prices are delayed at least 15 minutes.

Who is Roivant Sciences's CEO?

Mr. Matthew Gline is the chief executive officer of Roivant Sciences Ltd., which has about 721 employees.

What is the ROIV 52-week high?

The 52-week high for ROIV is $42.50 and the 52-week low is $19.96. The stock is currently 9.0% below its high.

Compare ROIV